Avista Pharma Solutions Completes Expansion of Analytical Laboratories At Durham Headquarters

DURHAM, N.C.–(BUSINESS WIRE)–#Avista—Avista
Pharma Solutions, Inc. (“Avista Pharma”) has announced that the
expansion and upgrades to the Analytical Laboratories at its Durham,
North Carolina facility are now complete. These enhancements will enable
the company to significantly increase its capacity with a comprehensive
range of capabilities for its pharmaceutical and medical device clients.

Comprised of two laboratories, the Analytical Research and Development
(ARD) and Quality Control (QC) labs have now doubled in size and
expanded the service offerings as the result of Avista’s capital
investment. The completed Analytical Laboratories’ systems and equipment
include a Thermo Scientific Orbitrap High-Resolution Mass Spectrometer,
Mass-Directed Preparative Chromatography, Agilent UPLC-tandem Quad MS,
Waters H-class UPLCs with six-column switching capabilities and
PDA/ELSD/CAD/Single Quad MS detectors, along with upgraded Laboratory
Information Management System (LIMS), Empower™ 3 Chromatography Data
Software and Agilent MassHunter software with Enterprise Content Manager.

“Expanding our laboratory and adding new service offerings reinforces
our commitment to providing our clients with a world-class center of
excellence to assist in their product development efforts,” said Patrick
Walsh, Chief Executive Officer at Avista. “Our clients choose to work
with us because our skilled teams are relentless in support of their
project needs.”

Using these state-of-the-art systems and equipment, Avista’s
full-service offering includes:

• Chromatographic method development for assay and related substances,
  potential genotoxic impurities, organic volatile impurities and
  residual solvents
• Spectral identification using upgraded FTIR, NMR and UV-Vis
  instrumentation
• Structural chemistry and impurity identification through accurate mass
  LC-MS and generation fragmentation (MSn), 1D and 2D NMR and
  preparative chromatography isolation
• Fate and purge studies
• Extractable/leachable studies
• Release and stability testing

For more information about the Analytical Laboratories at all three of
Avista’s facilities, please visit www.avistapharma.com.

NEW MEDIA CONTENT:

Avista Pharma on Facebook
https://www.facebook.com/AvistaPharma

Avista Pharma on Twitter
https://twitter.com/avistapharma

Avista Pharma on LinkedIn
https://www.linkedin.com/company/avista-pharma-solutions

ABOUT AVISTA PHARMA SOLUTIONS, INC.:

Avista Pharma, a portfolio company of Ampersand Capital Partners, is a
contract testing, development and manufacturing organization (CDMO)
encompassing more than 200,000 square feet of laboratory and
manufacturing space across three locations (Agawam, Massachusetts;
Durham, North Carolina and Longmont, Colorado), providing
pharmaceutical, animal health and medical device clients a broad suite
of scientifically-differentiated services, ranging from early stage API
and Drug Product discovery, development and cGMP manufacturing, to
standalone analytical and microbiology testing support. For more
information about Avista Pharma Solutions, Inc., please visit us at www.avistapharma.com.

ABOUT AMPERSAND CAPITAL PARTNERS:

Ampersand is a middle market private equity firm with a focus on growth
equity investments in the healthcare sector. Over the past two decades,
Ampersand has managed more than $1 billion in private equity
partnerships. Ampersand leverages its unique blend of private equity and
operating experience to build value and drive superior long-term
performance alongside its portfolio company management teams. Additional
information about Ampersand is available at www.ampersandcapital.com.

Contacts

MMI Public Relations
Gineen Cargo, 919-233-6600
[email protected]